Price: USD 5075.78/kg
MOQ: 1 kg
Molecular Weight: 341.411
Name: 1-Prrolidineacetamide 2-0x0-N-(5,6.7.8-tetrahydro-2,3-dimethyfuro[2,3-bJquinolin-4-y)-
Synonyms: Y1294; D01MHI; AN-469; EX-A739; 463c819; mkc-231; CS-2196; bci-540; mkc 231; DS-14004; HY-17553; AJ-08232; J-690145; AK-41975;
ZINC4939; AC1L4WO1; PL045003; PL006617; TC-072260; KB-271979; AX8209310; CTK8D3778; ST2407347; 114-13061; v6f16o5gr7; FT-0697594; 4CH-
017490; K-0000OFA: CHEMBL 37935; coluracetam; mfcd00901416; AKOS015842255; SCHEMBL194780; DTXSID60159386; uni-v6f16o5gr7;
coluracetam [inn]; Coluracetam, =99%; MOLPOR...
Classification: Other Chemicals
Cas NO.: 135463-81-9
Molecular Formula: C19H23N3O3
Boiling Point: 634.1°C at 760 mmHg
Flash Point: 337.3°C
usage: a nootropic drug of the racetam family
Brand Name: myland
Appearance:white crystalline powder
Packaging & Delivery
Packaging Detail: 1kg/bag.
Chemical name: N-(2,3-Dimethyl-5,6,7,8-tetrahydrofuro[2,3-b]quinolin-4-yl)-2-(2-oxopyrrolidin-1-yl)acetamide.
Appearance: white crystalline powder
Coluracetam (BCI-540) is a nootropic drug of the racetam family.Coluracetam (formerly known as MKC-231) was initially developed and tested by the Mitsubishi Tanabe Pharma Corporation for Alzheimer's disease. After the drug failed to reach endpoints in its clinical trials it was in-licensed by BrainCells Inc for investigations into major depression disorder (MDD), after being awarded a "Qualifying Therapeutic Discovery Program Grant" by the state of California.Findings from its Phase 2a clinical trials have suggested that it would be an ideal medication for co-morbid MDD with generalized anxiety disorder (GAD).BrainCells Inc is currently out-licensing the drug for this purpose.It may also have potential use in prevention and treatment of ischemic retinopathy and retinal and optic nerve injury.
Coluracetam enhances high-affinity choline uptake (HACU) which is the rate-limiting step of acetylcholine (ACh) synthesis, and is the only known choline uptake enhancer to currently exist. Studies have shown Coluracetam to improve learning impairment on a single oral dose given to rats which have been exposed to cholinergic neurotoxins. Subsequent studies have shown that it may induce long-lasting procognitive effects by changing the choline transporter regulation system.
*Your email address will not be published. Required fields are marked.